We will now discuss in detail evidence for PSC existence and development and detail the potential use of the Sclerostin antibody and parathyroid hormone (Pth) in treatment of bone loss from periodontal disease or other craniofacial trauma. This evidence concerns the gene SOST and periodontal disorder.